ADMA Biologics (NASDAQ:ADMA) Trading Up 8.8% – Here’s Why

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) traded up 8.8% on Monday . The stock traded as high as $21.18 and last traded at $21.11. 4,282,141 shares traded hands during mid-day trading, an increase of 20% from the average session volume of 3,567,260 shares. The stock had previously closed at $19.40.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

The business has a 50-day moving average of $17.96 and a 200 day moving average of $18.19. The firm has a market capitalization of $5.17 billion, a P/E ratio of 77.78 and a beta of 0.53. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Hedge Funds Weigh In On ADMA Biologics

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after acquiring an additional 80,302 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of ADMA Biologics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after acquiring an additional 50,399 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock valued at $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Renaissance Technologies LLC boosted its position in ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock worth $64,654,000 after purchasing an additional 102,692 shares during the period. Finally, Perpetual Ltd purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at approximately $62,300,000. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.